PT - JOURNAL ARTICLE AU - Parizad Varghaei AU - Grace Yoon AU - Mehrdad A Estiar AU - Simon Veyron AU - Nicolas Dupre AU - Jean-François Trempe AU - Guy A Rouleau AU - Ziv Gan-Or TI - <em>GCH1</em> mutations in hereditary spastic paraplegia AID - 10.1101/2021.01.14.21249305 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.14.21249305 4099 - http://medrxiv.org/content/early/2021/01/20/2021.01.14.21249305.short 4100 - http://medrxiv.org/content/early/2021/01/20/2021.01.14.21249305.full AB - GCH1 mutations have been associated with dopa-responsive dystonia (DRD), Parkinson’s disease (PD) and tetrahydrobiopterin (BH4)-deficient hyperphenylalaninemia B. Recently, GCH1 mutations have also been reported in five patients with hereditary spastic paraplegia (HSP). In this study, a total of 400 HSP patients (291 families) from different centers across Canada were analyzed by whole exome sequencing (WES). Three patients with GCH1 variants were identified: monozygotic twins with a p.(Ser77_Leu82del) variant, and a patient with a p.(Val205Glu) variant. Both variants were predicted to be likely pathogenic. The three patients presented with childhood-onset spasticity in the lower limbs, hyperreflexia and abnormal plantar responses. Only one of the patients had diurnal fluctuations, and none had parkinsonism or dystonia. Phenotypic differences between the monozygotic twins were observed, and they responded well to levodopa treatment. Pathway enrichment analysis suggested that GCH1 shares similar processes and pathways with other HSP-associated genes, and structural analysis of the variants suggested a disruptive effect. In conclusion, GCH1 mutations may also cause HSP; therefore, we suggest including GCH1 in the screening panels of HSP genes. Clinical differences between monozygotic twins suggest that environmental factors could play a role in the clinical presentation of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by CIHR Emerging Team Grant, in collaboration with the Canadian Organization for Rare Disorders (CORD), grant number RN127580 – 260005, and by a CIHR Foundation grant granted to GAR. MAE is funded by the Fonds de Recherche du Quebec-Sante (FRQS). SV holds a Basic Research Fellowship from Parkinson Canada. JFT holds a Canada Research Chair (Tier 2) in Structural Pharmacology. GAR holds a Canada Research Chair (Tier 1) in Genetics of the Nervous System and the Wilder Pen field Chair in Neurosciences. ZGO is supported by the Fonds de recherche du Quebec-Sante Chercheur-Boursier award and is a Parkinson Canada New Investigator awardee.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants have signed an informed consent form prior to enrollment, and the McGill University Health Center (MUHC) Research Ethics Board (REB) have approved the study protocols, REB number IRB00010120.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request from the authors.